Gotowa bibliografia na temat „LDL/HDL”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „LDL/HDL”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "LDL/HDL"
J.-M.M. "LDL, oui, mais HDL?" Revue Francophone des Laboratoires 2007, nr 392 (maj 2007): 15. http://dx.doi.org/10.1016/s1773-035x(06)80621-0.
Pełny tekst źródłaAmrullah, Amran, Budi Handono i Akhmad Yogi Pramatirta. "Rasio Low Density Lipoprotein dan High Density Lipoprotein pada Preeklamsi Berat dibandingkan dengan Kehamilan Normal di Rumah Sakit Dr. Hasan Sadikin Bandung". Indonesian Journal of Obstetrics & Gynecology Science 2, nr 1 (29.03.2019): 67. http://dx.doi.org/10.24198/obgynia.v2i1.79.
Pełny tekst źródłaFujihara, Kazuya, Hiroaki Suzuki, Akira Sato, Satoru Kodama, Yoriko Heianza, Kazumi Saito, Hitoshi Iwasaki i in. "Circulating Malondialdehyde-Modified LDL-Related Variables and Coronary Artery Stenosis in Asymptomatic Patients with Type 2 Diabetes". Journal of Diabetes Research 2015 (2015): 1–8. http://dx.doi.org/10.1155/2015/507245.
Pełny tekst źródłaBaruch, Lawrence, Valerie J. Chiong, Sanjay Agarwal i Bhanu Gupta. "Discordance of Non-HDL and Directly Measured LDL Cholesterol: Which Lipid Measure is Preferred When Calculated LDL Is Inaccurate?" Cholesterol 2013 (23.04.2013): 1–6. http://dx.doi.org/10.1155/2013/502948.
Pełny tekst źródłaGarcia-Rios, Antonio, Dragana Nikolic, Pablo Perez-Martinez, Jose Lopez-Miranda, Manfredi Rizzo i Ron Hoogeveen. "LDL and HDL Subfractions, Dysfunctional HDL: Treatment Options". Current Pharmaceutical Design 20, nr 40 (14.10.2014): 6249–55. http://dx.doi.org/10.2174/1381612820666140620154014.
Pełny tekst źródłaBenitez, S., C. Bancells, J. Ordonez-Llanos i J. L. Sanchez-Quesada. "HDL COUNTERACTS INFLAMMATORY PROPERTIES OF ELECTRONEGATIVE LDL (LDL(-))". Atherosclerosis Supplements 9, nr 1 (maj 2008): 50. http://dx.doi.org/10.1016/s1567-5688(08)70195-8.
Pełny tekst źródłaPian, M. S., i L. G. Dobbs. "Lipoprotein-stimulated surfactant secretion in alveolar type II cells: mediation by heterotrimeric G proteins". American Journal of Physiology-Lung Cellular and Molecular Physiology 273, nr 3 (1.09.1997): L634—L639. http://dx.doi.org/10.1152/ajplung.1997.273.3.l634.
Pełny tekst źródłaEnomoto, Mika, Hisashi Adachi, Yuji Hirai, Ako Fukami, Akira Satoh, Maki Otsuka, Shun-Ichi Kumagae i in. "LDL-C/HDL-C Ratio Predicts Carotid Intima-Media Thickness Progression Better Than HDL-C or LDL-C Alone". Journal of Lipids 2011 (2011): 1–6. http://dx.doi.org/10.1155/2011/549137.
Pełny tekst źródłaMiida, Takashi, Yuichi Nakamura, Toru Mezaki, Osamu Hanyu, Seitaro Maruyama, Yoshinori Horikawa, Sachiko Izawa, Yukio Yamada, Hiroshi Matsui i Masahiko Okada. "LDL-cholesterol and HDL-cholesterol concentrations decrease during the day". Annals of Clinical Biochemistry: International Journal of Laboratory Medicine 39, nr 3 (1.05.2002): 241–49. http://dx.doi.org/10.1258/0004563021901946.
Pełny tekst źródłaKarádi, I., L. Romics, P. Kempler, I. Balogh, I. Szilvási i L. Littmann. "HDL protection against atherogenic LDL?" Basic Research in Cardiology 82, nr 6 (listopad 1987): 596–97. http://dx.doi.org/10.1007/bf01907230.
Pełny tekst źródłaRozprawy doktorskie na temat "LDL/HDL"
Zerrad-Saadi, Amal. "Stress oxydant et LDL : mécanismes de l'effet protecteur des HDL". Paris 5, 2008. http://www.theses.fr/2008PA05P640.
Pełny tekst źródłaThe capacité of HDL to protect LDL against oxidative stress is well established. However, mechanisms involved in such activity remain undetermined. Our firts aim was to assess the relationship between physicochemical properties of sub-fractions of LDL and their antiatherogenic in particular antioxidative (AOX) activities. We have demonstrated that HDL3 is depleted in spingomyelin and enriched in spingosine-1-phosphate as compared to HDL2. In addition, HDL3 displayed an elevated ratio of apolipoprotein AI (apoAI) to apoAII, and increased activities of HDL-associated enzymes with AOX properties. We have also studied mechanisms involved in the AOX activity of HDL Our data suggest a two-step mechanism involving transfer of phospholipids hydroperoxides (PLOOH) from oxidized LDL to HDL ; this step is influenced by the fluidity of the PL monolayer de HDL, and the reduction of PLOOH to redox-inactive PLOH largely through the action of two methionine residues of apoAI. This study emphasizes the importance of HDL in mitigating potential atherogenecity of LDL
Brindisi, Marie-Claude. "Relaxation vasculaire et HDL : rôle de la glycation et de l'oxydation des HDL sur la capacité de ces HDL à contrecarrer les effets inhibiteurs des LDL oxydées sur la vasorelaxation endothélium-dépendante". Thesis, Dijon, 2012. http://www.theses.fr/2012DIJOMU05.
Pełny tekst źródłaContrary to HDL from normolipidaemic and normoglycaemic subjects, HDL from diabetic patients have lost their capacity to reverse the inhibition of vasorelaxation induced by oxidized LDL. Mechanisms involved are unknown. The glycation and oxidation of HDL are two major phenomena in diabetes mellitus. The aim of this work was to study in vitro the role of glycation (with or without spontaneous oxidation) and oxidation of HDL, on their capacity to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation. Each state showed the same result, modified HDL lost their vasorelaxing power in stress conditions (with oxidized LDL). Nevertheless, modified HDL alone (without oxidized LDL) did not alter vasorelaxation induced by acetylcholine, after noradrenaline-induced vasoconstriction. Thus, modifications of HDL induce a loss of the ability to protect vessels from oxidative stress rather than have a direct deleterious effect on the vessel. One of the major mechanisms involved in this phenomenon is probably the loss of SR-BI binding of these modified HDL, that could lead to the inability of HDL to protect caveolae from deleterious effects induced by oxidized LDL and could not preserve NO production. However, though glycation, like oxidation of HDL, leads to these deleterious effects, it would seem that during physiopathological conditions, with the spontaneous oxidation of glycated HDL, oxidation does not aggravate the loss of the capacity of diabetic HDL to counteract the inhibitory effect of oxidized LDL on endothelium-dependent vasorelaxation
Andersson, Mari. "Har kost och statiner var för sig eller i kombination någon effekt på LDL och HDL?" Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2019. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-82401.
Pełny tekst źródłaBackground: Cholesterol is an important part in our cells. Cholesterol stabilize cell membranes and is needed for the synthesis of estrogen, testosterone, cortisol, vitamin D and in the formation of bile acid. Cholesterol is synthesized in the liver but the body also absorbs cholesterol from the diet. The transport of cholesterol in the blood is taken care of by LDL and HDL. When the levels of LDL are increased and HDL are decreased there is an increased risk of developing atherosclerosis and cardiovascular diseases which are the main cause of death in the western countries. Purpose: One of three different purposes of this presented study was to evaluate if the levels of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were changed when following different diets. The second purpose was to study the change in levels of LDL and HDL change after treatment with statins as monotherapy or in combination with ezetimibe. The third part of this study was to see how LDL and HDL were changed when different diets were combined with statins. Method: This work was a literature study based on seven different randomized controlled trials that were found in the database PubMed. Three of the studies evaluated the role of the different diets when aiming at reducing the cholesterol levels. In two of the studies patients were either treated with atorvastatin as monotherapy or with atorvastatin plus ezetimib. The last two studies evaluated the use of simvastatin in combination with LCHF-diet as compared to the use of simvastatin plus ezetimib which were used in combination with a LCHF-diet. Results: The results showed that weight reduction and the choice of a specific diet are important factors when aiming at a decrease in levels of LDL and an increase in levels of HDL. Moreover, results obtained also suggested that statins, when used in combination with ezetimibe, gave the largest effect and was found to decrease levels of LDL and increase levels of HDL. According to the results, it may be concluded that the controlled release of simvastatin has an equivalent effect on these levels regardless if administered in the morning or in the evening. Conclusion: The results obtained in this work suggest that weight reduction and eating according to a diet that consists of a low proportion of carbohydrates may be a good and safe approach to reduce the levels of LDL and increase the levels of HDL. Statins can be considered to be the first alternative to treat dyslipidemia and should be used at elevated levels of cholesterol. To achieve the best result, an analysis of the selected literature in this work, suggest that a low-carbohydrate diet should be combined with the use of statins and ezetimibe.
Marangoni, Adriane Bueno. "Baixa suplementação de azeite de oliva reduz triaciglicerois e características lipídicas e oxidativas associadas à lipoproteína de baixa densidade em indivíduos com risco cardiovascular intermediário e alto". Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/6/6138/tde-21102014-100904/.
Pełny tekst źródłaIntroduction: Cardiovascular disease is the leading cause of premature morbidity and mortality worldwide, and accounts for a large part of the costs of resources devoted to public policy programs. In this context, the diet is an important tool in managing and reducing the risk of cardiovascular disease. Given that numerous studies show that consumption of omega 9 or food source changes positively several classical cardiovascular risk factors, it becomes important to evaluate its effect on physicochemical properties of LDL and HDL, cardiometabolic and oxidative markers in Brazilian individuals with different levels of cardiovascular risk. Objective: This study aimed to evaluate the effect of consuming olive oil on classical and new cardiometabolic properties in individuals with different levels of cardiovascular risk. Methods: It was a clinical, prospective, randomized, placebo controlled, double blind study based on nutritional intervention. Individuals of both sexes, divided into groups olive oil (AO) and placebo (PL) for 8 weeks received 3 g/d of olive oil or placebo. All subjects were classified for cardiovascular risk following the criteria established by the Framingham Risk Score (FRS). At baseline period, T = 4W and T = 8W the clinical profile, the family history of diseases, blood pressure, food consumption and physical activity level were determined. From plasma or serum obtained after 12 h of fasting lipid profile, apolipoproteins, the size of LDL and HDL, LDL (-) and NEFAS content, and activity of paraoxonase were determined. Adherence to the intervention was monitored by direct means (biochemical markers) and indirect (register of complications). Results: The olive oil was effective in reducing the concentration of triacylglycerol of individuals at high cardiovascular risk (p = 0.023 at T=4W and p=0.049 at T=8W) and LDL-C in individuals with intermediate cardiovascular risk (p=0.045 at T=8W) in the current study. It was also observed a significant reduction in LDL (-) when the sample was divided by the FRS. However, changes in other parameters were not detected when comparing the intervention group and the placebo group. Conclusion: Even at low dosage, olive oil has proved to be beneficial in reducing triglycerides, LDL-C and LDL (-).It is therefore recommended the incorporation of olive oil in the Brazilian diet even in low doses. It is suggested that future studies to use higher doses in order to check additional benefits associated with olive oil consumption.
Santos, Andreza Oliveira dos [UNIFESP]. "Relação entre os títulos de anticorpos anti LDLox e marcadores do risco cardiovascular". Universidade Federal de São Paulo (UNIFESP), 2008. http://repositorio.unifesp.br/handle/11600/10030.
Pełny tekst źródłaConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Objetivos: As lipoproteínas oxidadas e os anticorpos anti-LDL oxidada (anti-LDLox) têm sido detectados no plasma e em lesões ateroscleróticas em humanos. No entanto, o papel destes autoanticorpos na proteção vascular ou na patogênese das síndromes coronarianas agudas (SCA) permanece não elucidado. Nós examinamos a relação entre os títulos de IgG humana anti-LDLox com marcadores de risco para a doença cardiovascular. Métodos: Títulos de autoanticorpos anti-LDLox foram mensurados em indivíduos portadores de hipertensão arterial em estágio 1 (n=94), sem outros fatores de risco, e em indivíduos com síndrome metabólica após recente síndrome coronariana aguda (n=116). Os autoanticorpos contra a LDL oxidada pelo cobre foram avaliados por ELISA. Resultados: pacientes com hipertensão arterial apresentaram menor índice de massa corpórea e circunferência abdominal, maiores níveis de pressão arterial sistólica e diastólica quando comparados aos portadores de SCA (p<0,001). O HDL-C e a Apo A1 foram maiores, enquanto os triglicérides e a Apo B foram menores nos pacientes do grupo hipertensão em estágio 1 (p<0,0001). Os títulos de anticorpos anti-LDLox foram maiores no grupo hipertensão comparados aos do grupo SCA, e os hipertensos do primeiro grupo apresentaram níveis de PCR menores do que indivíduos com SCA (p<0,0001). A análise conjunta de ambos os grupos mostrou, em análise univariada, significante correlação inversa para a PCR (r=-0,284), IMC (r=-0,256), circumferência abdominal (r=-0,368), apo B (r=-0,191) e glicemia (r=-0,303) e correlações positivas entre pressão arterial sistólica e diastólica (r=0,319 e r=0,167, respectivamente), HDL-C e Apo A1 (r=0,224 e r=0,257, respectivamente), com os títulos de anticorpos anti-LDLox (p<0,02). Regressão linear múltipla mostrou que a PCRas, glicemia e circunferência abdominal permaneceram independente e negativamente associados com os títulos de anticorpos anti-LDLox. Conclusões: nossos resultados sugerem que os títulos baixos de anticorpos circulantes anti-LDLox possam estar associados com maior risco cardiovascular.
Objectives: Oxidized lipoproteins and antibodies anti-oxidized LDL (anti-oxLDL) have been detected in human plasma and in atherosclerotic lesions. However, the role of these autoantibodies in the maintenance of health or in the pathogenesis of acute coronary syndromes (ACS) remains unclear. We examined the relationship of human IgG antibodies anti- ox LDL with cardiovascular disease risk markers. Methods: Titers of human anti-oxLDL were measured in hypertensive subjects in stage 1 (n=94) without other risk factors, and in individuals with metabolic syndrome after recent acute coronary syndrome (n=116). Autoantibodies against copper ion oxidized LDL were measured by ELISA. Results: Hipertensive patients presented lower BMI, waist circunference, higher blood pressure levels than those with ACS (p<0.001). HDL-C and Apo A1 were higher, whereas triglycerides and Apo B were lower in those with hypertension stage 1 (p<0.0001). Anti-oxLDL titers were higher in hypertensive patients compared to those with acute coronary syndromes, and hypertensive patients presented lower hs-CRP than those with ACS (p<0.0001). Taken into account both populations, univariate analysis showed small, but significant inverse correlations between the hs-CRP (r=-0.284), BMI (r=-0.256), waist circunference (r=-0.368), apo B (r= -0.191), and blood glucose (r= - 0.303) and positive correlations between systolic and diastolic blood pressure (r=0.319 and r=0.167, respectively), HDL-C and Apo A1 (r=0.224 and r=0.257, respectively), with anti-ox LDL titers (p<0.02). After multiple linear regression, hs-CRP, fasting glycemia and waist circunference remained independently associated with anti-oxLDL. Conclusions: Our results suggest that low titers of circulating anti-oxLDL antibodies may be associated with increased cardiovascular risk.
TEDE
BV UNIFESP: Teses e dissertações
Spessatto, Débora. "Associação dos níveis de HbA1c com colesterol LDL e colesterol LDL oxidado em indivíduos não-diabéticos". reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2011. http://hdl.handle.net/10183/39649.
Pełny tekst źródłaBackground: Diabetes mellitus (DM) is associated with chronic microvascular and macrovascular complications. The measurement of glycated hemoglobin (HbA1c) assesses the degree of glycemic control in diabetics patients and their levels are able to predict the risk of developing these complications. The formation of advanced glycation and products (AGEs) and oxidative stress are some of the hypothesis described to explain the diabetic complications. The reaction of nonenzymatic glycation of proteins is also related to these complications and is responsible for the formation of HbA1c. However, it has been shown an increase in glycation in nondiabetic patients, which is maybe due to lipid peroxidation, consequently, the levels of malondialdehyde (MDA) increase and there is modifications in the apolipoprotein B (apoB) of low-density cholesterol (LDL). The oxidative modification of LDL confers specific proatherogenic properties. The presence of oxidized LDL and an increased tendency to LDL peroxidation contribute to increased levels of HbA1c in diabetic patients. Objective: To investigate the association between HbA1c levels and the levels of LDL cholesterol and oxidized LDL in subjects without diabetes. Methods: We conducted an observational cross-sectional study in which a total of 196 individuals, classified as non-diabetics, were analyzed and divided into three groups according to the values of HbA1c and fasting plasma glucose (FPG): Group 1 (n = 64) - HbA1c <5.7% and FPG <100 mg / dL, Group 2 (n = 69) - HbA1c ≥ 5.7 and ≤ 6.4% and FPG <100 mg / dL, Group 3 (n = 63) - HbA1c ≥ 5.7 and ≤ 6.4% and FPG ≥ 100 and <126mg/dL. Samples of whole blood and serum were collected. Oxidized LDL was measured by enzyme immunoassay method (Mercodia ®), ApoB was measured by imunoturbidimentria and the ratio LDL cholesterol (oxi) / HDL-cholesterol was estimated. Other biochemical measurements of lipid profile were also carried out. Results: There were significant differences in LDL (oxi) (p <0.001), Apo B (p = 0.026), and ratio LDL (oxi) / HDL (p <0.001) between the three groups. HbA1c values showed positive association with LDL (oxi) (r = 0.431, p <0.001), LDL (r = 0.148, p = 0.039), non-HDL Col (r = 0.192, p = 0.007) and Apo B (r = 0.171, p <0.001). These positive associations remained significant even after adjustment for multiple linear regression analysis for variables such as alcohol, drugs, BMI and age. The ratio LDL (oxi) / HDL (r = 0.422, p <0.001), CT (r = 0.142, p = 0.048), triglycerides (r = 0.155, p = 0.030) and BMI (r = 0.263, p <0.001) also showed positive correlations with HbA1c values. Conclusions: Our study demonstrated that there is association between HbA1c levels and the atherogenic lipid particles LDL, Apo B, non-HDL cholesterol and LDL (oxi). LDL levels, especially LDL (oxi), are significantly associated with HbA1c and glucose levels, even in non-diabetics. Individuals classified with high risk of developing diabetes or CVD have higher levels of oxidized LDL particles. Our data suggest that the presence of LDL (oxi) is related to glycation and increased blood levels of HbA1c in nondiabetic individuals.
Schofield, Jonathan. "HDL functionality and lipoprotein quality in diabetes mellitus". Thesis, University of Manchester, 2017. https://www.research.manchester.ac.uk/portal/en/theses/hdl-functionality-and-lipoprotein-quality-in-diabetes-mellitus(a164e8f2-692a-4ac8-aa29-5e8f31d3c217).html.
Pełny tekst źródłaFreitas, Maria Camila Pruper de. "Papel do ômega-3 nas características físico-químicas da HDL e LDL e possível associação com medidas Z-scan em indivíduos adultos". Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/6/6138/tde-17092015-094133/.
Pełny tekst źródłaIntroduction: The increased of cardiovascular disease prevalence draws attention to the need to adopt effective and inexpensive strategies as preventive measures to reduce risk factors, morbidity and deaths from coronary events. Lifestyle modification is indicated as first alternative to be adopted. In this context the diet stands out and omega-3 polyunsaturated fatty acids benefits on cardiovascular health are largely recognized. Cardiovascular diseases are influenced by several risk factors and the plasma imbalance lipoprotein is considered a crucial independent risk factor. However, there is evidence of the influence of lipoprotein subfractions in cardiovascular risk, based on the physicochemical characteristics of these particles. The development of new techniques able to identify those parameters has been the focus of great scientific interest. Objective: To evaluate the role of omega-3 on HDL and LDL physicochemical characteristics and possible association between Z-scan measurements and cardiometabolic markers in adults. Methods: From a subsample of the study CARDIONUTRI (clinical, randomized, controlled, double blind study with 8-week follow-up) were selected 36 individuals from the Omega-3 Group (3.0g/day of fish oil - 1,11g EPA + 0.69g DHA) and 27 individuals from the Placebo Group (3.0g/day of mineral oil). The clinical profile, family history, dietary intake, physical activity and anthropometry were monitored. Blood samples were collected after 12 hours of fasting to evaluate plasma concentrations of TC, TAG, HDL-C, LDL-C, APOAI, APOB, PON1 and glucose. The HDL and LDL size was analyzed by the standard method Lipoprint®. The levels of LDL (-) was determined by ELISA. The Z-scan measurements were determined by thermal diffusivity and linear absorption of LDL (1.0 mg / dL protein) isolated by ultracentrifugation. All study variables were evaluated at baseline and after 8 weeks of intervention. The intervention accession was monitored by capsule count and percentage of plasma fatty acids. To evaluate the association of the Z-Scan measurements to cardiometabolic markers, the data collected at baseline were subjected to Principal Component Analysis. Results: The average age of individuals were 51.5 (10.5) years. The omega-3 supplementation promoted a significant decreased of TC, TAG, non-HDL, small HDL and LDL(-), and significantly increased HDL-C and large HDL. The omega-3 was more effective in reducing the TAG (29.2 per cent ) when compared to placebo (2.9 per cent ). The Omega-3 Group increased large HDL (16.9 per cent ) and decreased small HDL (-16.3 per cent ) after the intervention, with significant difference when compared to the Placebo Group that decreased large HDL (-4.8 per cent ) and increased small HDL (17.7 per cent ). There were no differences in Z-scan measurements with the interventions, but were observed positively associated the Z-scan measurements with the anti-atherogenic sample patterns and negatively associated with atherogenic sample patterns when the sample was standardized from the Principal Components Analysis. Conclusion: The omega-3 demonstrated positive effect on the lipid profile and atherogenic lipoprotein subfractions. Supplementation with omega-3 did not modify the Z-scan measurements, however, the technique proved to be a tool that can be associated with atherogenic and anti-atherogenic sample patterns monitored in this study.
Karlsson, Helen. "Lipoproteomics : A New Approach to the Identification and Characterization of Proteins in LDL and HDL". Doctoral thesis, Linköping : Univ, 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-8527.
Pełny tekst źródłaYadav, Rahul. "HDL functionality and LDL quality : the influence of obesity, obstructive sleep apnoea and pharmacological intervention". Thesis, University of Manchester, 2013. https://www.research.manchester.ac.uk/portal/en/theses/hdl-functionality-and-ldl-quality-the-influence-of-obesity-obstructive-sleep-apnoea-and-pharmacological-intervention(60e83156-3d19-4ccb-999c-f57ac5c6ca46).html.
Pełny tekst źródłaKsiążki na temat "LDL/HDL"
S, Pagano Irwin, i Strait Nathan B, red. HDL and LDL cholesterol physiology and clinical significance. Hauppauge, NY: Nova Science Publishers, 2009.
Znajdź pełny tekst źródłaGotō, Yūichirō. Global perspectives in lipid management: Regulating LDL-cholesterol, HDL-cholesterol, and triglycerides : their role in primary prevention of CHD. London: Royal Society of Medicine Press, 1998.
Znajdź pełny tekst źródłaJohnston, Philip. A study regarding the stability of peroxynitrite and its ability to oxidatively modify the protein moities of HDL and LDL cholesterol. [S.l: The Author], 1996.
Znajdź pełny tekst źródłaTurun yliopisto. Cardiorespiratory Research Unit. i Turun yliopisto. Dept. of Medicine., red. Factors influencing tracking of serum lipid values in children and young adults: A 9-year follow-up study. Turku: Turun Yliopisto, 1991.
Znajdź pełny tekst źródłaM, Gotto Antonio, i Gotō Yūichirō 1922-, red. Global perspectives in lipid management: Regulating LDL-cholesterol, HDL-cholesterol and triglycerides : their role in the primary prevention of CHD : proceedings of a symposium sponsored by Parke-Davis Pharmaceuticals held in London, UK, 9-10 October 1997. London: Royal Society of Medicine Press, 1998.
Znajdź pełny tekst źródła1924-, Scanu Angelo M., red. Lipoprotein (a). San Diego: Academic Press, 1990.
Znajdź pełny tekst źródłaWiklund, Olov, i Jan Borén. Pathogenesis of atherosclerosis: lipid metabolism. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198755777.003.0011.
Pełny tekst źródłaReiner, Željko, Olov Wiklund i John Betteridge. Lipids. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656653.003.0015.
Pełny tekst źródłaTwisk, Jos, i Isabel Ferreira. Physical activity, physical fitness, and cardiovascular health. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199232482.003.0025.
Pełny tekst źródłaCzęści książek na temat "LDL/HDL"
Qin, Shucun. "LDL and HDL Oxidative Modification and Atherosclerosis". W Advances in Experimental Medicine and Biology, 157–69. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-6082-8_10.
Pełny tekst źródłaKaplan, Marielle, Michael Aviram i Tony Hayek. "Lipoprotein (LDL and HDL) Oxidation in Diabetes Mellitus". W Contemporary Diabetes, 187–201. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7554-5_9.
Pełny tekst źródłaNavab, Mohamad, Susan Y. Hama, Alan C. Wagner, Greg Hough, Andrew D. Watson, Srinivasa T. Reddy, Brian J. Van Lenten, Hillel Laks i Alan M. Fogelman. "Protective Action of HDL-Associated PON1 Against LDL Oxidation". W Paraoxonase (PON1) in Health and Disease, 125–36. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-1027-7_6.
Pełny tekst źródłaStrang, A. C., i M. D. Trip. "Wat is belangrijker: een hoog HDL of een laag LDL?" W De meest gestelde vragen over: cholesterol, 48–54. Houten: Bohn Stafleu van Loghum, 2010. http://dx.doi.org/10.1007/978-90-313-7508-0_6.
Pełny tekst źródłaBarter, P. J., L. B. F. Chang i O. V. Rajaram. "Factors Regulating the Distribution of Cholesterol Between LDL and HDL". W Hypercholesterolemia, Hypocholesterolemia, Hypertriglyceridemia, in Vivo Kinetics, 59–64. Boston, MA: Springer US, 1990. http://dx.doi.org/10.1007/978-1-4684-5904-3_6.
Pełny tekst źródłaSchwarz, Margrit, i Jae B. Kim. "Emerging Therapeutic Approaches for Dyslipidemias Associated with High LDL and Low HDL". W Metabolic Syndrome, 199–234. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9780470910016.ch8.
Pełny tekst źródłaBaudet, M. F., O. Esteva, M. Lasserre i B. Jacotot. "Cultured Fibroblast Interactions with LDL and HDL from Healthy Subjects on Various Dietary Fats". W Advances in Experimental Medicine and Biology, 189–94. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-1268-0_27.
Pełny tekst źródłaStein, Yechezkiel, i Olga Stein. "Fate of Cholesteryl Linoleyl Ether Injected Into Rats as Chylomicrons, Acetylated LDL and HDL". W Drugs Affecting Lipid Metabolism VIII, 37–46. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4613-2459-1_4.
Pełny tekst źródłaKostner, Gerhard M., Gabriele Knipping, Johanna E. M. Groener, Rudolf Zechner i Hans Dieplinger. "The Role of LCAT and Cholesteryl Ester Transfer Proteins for the HDL and LDL Structure and Metabolism". W Advances in Experimental Medicine and Biology, 79–86. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4684-1268-0_12.
Pełny tekst źródłaDachet, Christiane, Claude Motta, Danièle Neufcour i Bernard Jacotot. "Modifications in the Chemical Composition and Thermometric Behavior of LDL and HDL by Probucol in Type IIa Hyperlipoproteinemia". W Advances in Experimental Medicine and Biology, 179–84. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4613-0733-4_22.
Pełny tekst źródłaStreszczenia konferencji na temat "LDL/HDL"
Prabhu, Anmiv S., Alejandro Moraga, Michael Cecchini, Rafael Mulero, Stephen Olsen, Young I. Cho i Min Jun Kim. "Synthetic Nanoscale Architectures for Lipoprotein Separation". W ASME 2008 International Mechanical Engineering Congress and Exposition. ASMEDC, 2008. http://dx.doi.org/10.1115/imece2008-66535.
Pełny tekst źródłaSurya, I. E., i J. W. N. Akkerman. "HUMAN PLASMA PAF-ACETYLHYDROLASE, NORMALLY PRESENT IN LOW DENSITY LIPOPROTEINS, IS ASSOCIATED WITH HIGH DENSITY LIPOPROTEINS IN A PATIENT WITH LDL DEFICIENCY". W XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1642882.
Pełny tekst źródłaLiu, Yvonne, Johann-Georg Hocher, Shujuan Ma, Liang Hu, Huijun Chen, Xiaoli Zhang, Fei Gong, Bernhard Krämer, Ge Lin i Berthold Hocher. "LDL/HDL- und Gesamtcholesterol/HDL-Quotienten vor der Schwangerschaft sind starke Prädiktoren für Gestationsdiabetes bei künstlicher Befruchtung". W Diabetes. Umwelt. Leben. Perspektiven aus allen Blickwinkeln. Georg Thieme Verlag KG, 2024. http://dx.doi.org/10.1055/s-0044-1785424.
Pełny tekst źródłaPrabhu, Anmiv S., Talukder Zaki Jubery, Kevin Freedman, Rafael Mulero, Prashanta Dutta i Min Jun Kim. "High Throughput Nanofluidic Architectures for Nanoparticle Separation". W ASME 2009 International Mechanical Engineering Congress and Exposition. ASMEDC, 2009. http://dx.doi.org/10.1115/imece2009-10649.
Pełny tekst źródłaIlea, Mihai, Marius Turnea, Calin Corciova i Mariana Rotariu. "AN E-LEARNING TOOL FOR MATHEMATICAL MODEL OF CHOLESTEROL HOMEOSTASIS DEPENDING ON DIET AND AGES". W eLSE 2020. University Publishing House, 2020. http://dx.doi.org/10.12753/2066-026x-20-200.
Pełny tekst źródłados Santos Avelino Leal, Geovanna Ellen, juliana alencar i Daniele Rodrigues Carvalho Caldas. "O EFEITO DA DIETOTERAPIA NAS DISLIPIDEMIAS E METABOLISMO DO HDL E LDL: UMA REVISÃO". W ANAIS DO 1° CONGRESSO INTERNACIONAL CIêNCIA E SOCIEDADE. Galoa, 2023. http://dx.doi.org/10.17648/cics-2023-177795.
Pełny tekst źródłaKuksis, Arnis. "Hydrolysis of hydroxy PUFA GPC of plasma lipoproteins by group IIA, V and X sPLA2s". W 2022 AOCS Annual Meeting & Expo. American Oil Chemists' Society (AOCS), 2022. http://dx.doi.org/10.21748/jxxc8749.
Pełny tekst źródłaGomes, Karina, Maria Carvalho, Ramon Pereira, Henrique Guimarães, Antônio Teixeira, Alexandre Braga, Maira Barbosa, Wagner Junior i Paulo Caramelli. "MACHINE LEARNING-BASED ROUTINE LABORATORY VARIABLES SCREENING FOR ONE-YEAR COGNITIVE AND FUNCTIONAL DECLINE IN INDIVIDUALS AGED 75+ YEARS: THE PIETÀ STUDY". W XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda004.
Pełny tekst źródłaFATHIL, Noor Mahdi. "EFFECT OF THE ENERGY DRINK (TIGER) ON THE PARAMETERS OF LIPID PROFILEIN THE FEMALE ALBINO MICE". W III.International Scientific Congress of Pure,Appliedand Technological Sciences. Rimar Academy, 2021. http://dx.doi.org/10.47832/minarcongress3-5.
Pełny tekst źródłaMcEwen, Tim, John Flach i Nancy Elder. "Ecological Interface for Assessing Cardiac Disease". W ASME 2012 11th Biennial Conference on Engineering Systems Design and Analysis. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/esda2012-82974.
Pełny tekst źródłaRaporty organizacyjne na temat "LDL/HDL"
Cortés Ortigosa, Francisco, i María Pascual Mora. Characterization of the extraction method of extracellular vesicles by HDL and LDL contamination. Fundación Avanza, maj 2023. http://dx.doi.org/10.60096/fundacionavanza/2902022.
Pełny tekst źródłaHung, Hsuan-Yu, Hui-Hsiung Lai, Hui-Chuan Lin i Chung-Yu Chen. Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C: A network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, lipiec 2022. http://dx.doi.org/10.37766/inplasy2022.7.0055.
Pełny tekst źródłaZhao, Shaoping, Jiao Zhong, Caihong Sun i Junping Zhang. Effects of Aerobic Exercise on TC, HDL-C, LDL-C and TG in patients with hyperlipidemia : A protocol of Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, luty 2021. http://dx.doi.org/10.37766/inplasy2021.2.0037.
Pełny tekst źródłaGao, Hui, Chen Gong, Shi-chun Shen, Jia-ying Zhao, Dou-dou Xu, Fang-biao Tao, Yang Wang i Xiao-chen Fan. A systematic review on the associations between prenatal phthalate exposure and childhood glycolipid metabolism and blood pressure: evidence from epidemiological studies. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, czerwiec 2022. http://dx.doi.org/10.37766/inplasy2022.6.0111.
Pełny tekst źródłaChen, Jiankun, Yingming Gu, Lihong Yin, Minyi He, Na Liu, Yue Lu, Changcai Xie, Jiqiang Li i Yu Chen. Network meta-analysis of curative efficacy of different acupuncture methods on obesity combined with insulin resistance. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, sierpień 2022. http://dx.doi.org/10.37766/inplasy2022.8.0075.
Pełny tekst źródła